| Editor's Note: Voting is now open in #FierceMadness: The Best Biotech Name Tournament for the Sweet 16 round. Get your votes in! |
Today’s Big NewsMar 28, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By Nick Paul Taylor Gilead is bucking the trend in IL-12, handing Xilio Therapeutics $43.5 million upfront to get into the space after seeing rivals such as AstraZeneca and Bristol Myers Squibb retreat from the cytokine. Xilio shared the news alongside details of plans to pull back from another program and lay off 21% of its staff. |
|
|
|
By Max Bayer Moderna gave its clearest look yet at a third wave of vaccine products during the company's annual vaccines business review on Wednesday. Early-stage shots aimed at Epstein–Barr virus, norovirus and shingles could further solidify the biotech's infectious disease portfolio. |
By Nick Paul Taylor Ironwood Pharmaceuticals’ stargazing has identified a new frontier for apraglutide by generating early clinical evidence that the GLP-2 analog plays nicely with Incyte’s Jakafi in a rare disease. The company acquired the molecule last year through its $1 billion takeover of VectaBio. |
By Max Bayer Milestone Pharmaceuticals has resubmitted a new drug application to the FDA, with Aldeyra readying a similar ask for the second half of the year. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
By James Waldron Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. |
By James Waldron Avalo Therapeutics is handing over more than $22 million in stock and cash to acquire AlmataBio for a phase 2-ready monoclonal antibody for hidradenitis suppurativa. |
By Helen Floersh The FDA should audit the hiring practices of its Bioresearch Monitoring program to see whether its efforts to attract more investigators and improve drug trial oversight are paying off, particularly as retention has largely failed to improve, the GAO said in a new report. |
By Conor Hale The agency previously took the rare step of banning the use these devices in March 2020, but the FDA's ban was overturned on appeal in July 2021. |
By Zoey Becker Médecins Sans Frontières urged GLP-1 drug makers to "relinquish their stranglehold" on the products and license the meds to generics makers to boost access. |
By Paige Minemyer A new report finds that the federal government made nearly $236 billion in improper payments across entitlement programs last year, with Medicare and Medicaid a large source of payment errors. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
Tuesday, April 9, 2024 | 10am ET / 7am PT Register now to learn about the high costs of failed drug and device launches in the pharmaceutical industry. Gain insights into reasons behind failures and real-world examples like Velcade and Exubera. Navigate challenges from R&D to commercialization for greater success. Save your spot! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
